NKGN
Live News • Jul 03
NKGen Biotech Showcases Troculeucel Data and China Opportunities at 2026 BIOCHINA Forum NKGen Biotech said CEO Paul Y. Song, M.D., will present at the 2026 BIOCHINA Global Forum on troculeucel’s potential in Alzheimer’s disease, ALS, FTD and Parkinson’s disease, including an update on the Phase 2 trial in Alzheimer’s and discussion of regulatory and collaboration opportunities in China.
The company framed China as a focus for potential regulatory pathways and partnerships around troculeucel, which could affect how it funds and structures future development and commercialization if discussions progress.
NKGen Biotech’s stock trades at about $0.06, with a return of 20% year to date.
The BIOCHINA appearance puts NKGen Biotech’s lead program in front of a large life-sciences audience and signals that management is actively testing interest from Chinese regulators and partners. The value of this exposure depends on future trial results and any concrete agreements that may or may not follow. Announcement • May 21
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’S Disease Program NKGen Biotech, Inc. had announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer’s disease. The new sites include Rutgers Health in Newark, New Jersey, Alzheimer’s Disease Research Center in Albany, New York, and K2 Medical Research in Orlando, Florida. Together, these additions expand the Company’s U.S. clinical footprint and improve geographic access for patients in the Northeast and Southeast regions. The Company’s Alzheimer’s disease program has previously operated clinical trial sites primarily on the West Coast and in Orlando, Florida. The addition of the Northeast sites provides more convenient access for patients and referring physicians, supporting continued efforts to evaluate the investigational therapy in a broader patient population. All three newly added sites are now active and available for patient screening and enrollment as part of the ongoing Phase 2 trial. The expanded site network is expected to enhance enrollment capacity and support continued patient recruitment across multiple regions of the United States. The Company noted that clinical trial enrollment is influenced by multiple factors, including patient eligibility and regional referral patterns. While the expanded site network is expected to enhance enrollment capacity, there can be no assurance regarding the timing or rate of patient recruitment. Additional information on the trial, including contact details for the activated sites, can be found on ClinicalTrials.gov at: NCT06189963. Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name for SNK01 assigned by the World Health Organization. The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market. Announcement • Apr 10
NKGen Biotech, Inc. Presents Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia NKGen Biotech, Inc. announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts. The presentation will include an overview of the Company's expanding mechanistic dataset, including evidence that troculeucel selectively targets autoreactive T cells and may modulate key neuroinflammatory pathways implicated in disease progression. Clinical observations from early-stage studies, including encouraging biomarker trends and reductions in neuroinflammatory signals measured in cerebrospinal fluid, will be reviewed. These data build on previously reported preclinical and clinical findings and further support troculeucel’s potential as a differentiated, cell-based approach to treating neurodegenerative disorders with high unmet medical need. Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market. 
